| pubmed-article:18955563 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18955563 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18955563 | lifeskim:mentions | umls-concept:C0001792 | lld:lifeskim |
| pubmed-article:18955563 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:18955563 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:18955563 | pubmed:issue | 15 | lld:pubmed |
| pubmed-article:18955563 | pubmed:dateCreated | 2009-4-10 | lld:pubmed |
| pubmed-article:18955563 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18955563 | pubmed:abstractText | We compared thalidomide-dexamethasone (TD) with melphalan-prednisolone (MP) in 289 elderly patients with multiple myeloma (MM). Patients received either thalidomide 200 mg plus dexamethasone 40 mg, days 1 to 4 and 15 to 18 on even cycles and days 1 to 4 on odd cycles, during a 28-day cycle or to melphalan 0.25 mg/kg and prednisolone 2 mg/kg orally on days 1 to 4 during a 28- to 42-day cycle. Patients achieving stable disease or better were randomly assigned to maintenance therapy with either thalidomide 100 mg daily and 3 MU interferon alpha-2b thrice weekly or to 3 MU interferon alpha-2b thrice weekly only. TD resulted in a higher proportion of complete and very good remissions (26% vs 13%; P= .006) and overall responses (68% vs 50%; P= .002) compared with MP. Time to progression (21.2 vs 29.1 months; P= .2), and progression-free survival was similar (16.7 vs 20.7 months; P= .1), but overall survival was significantly shorter in the TD group (41.5 vs 49.4 months; P= .024). Toxicity was higher with TD, particularly in patients older than 75 years with poor performance status. The study was registered at ClinicalTrials.gov as NCT00205751. | lld:pubmed |
| pubmed-article:18955563 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18955563 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18955563 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18955563 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:18955563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18955563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18955563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18955563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18955563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18955563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18955563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18955563 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18955563 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:18955563 | pubmed:issn | 1528-0020 | lld:pubmed |
| pubmed-article:18955563 | pubmed:author | pubmed-author:GreilRichardR | lld:pubmed |
| pubmed-article:18955563 | pubmed:author | pubmed-author:DrachJohannes... | lld:pubmed |
| pubmed-article:18955563 | pubmed:author | pubmed-author:SpickaIvanI | lld:pubmed |
| pubmed-article:18955563 | pubmed:author | pubmed-author:ZojerNiklasN | lld:pubmed |
| pubmed-article:18955563 | pubmed:author | pubmed-author:LudwigHeinzH | lld:pubmed |
| pubmed-article:18955563 | pubmed:author | pubmed-author:GisslingerHei... | lld:pubmed |
| pubmed-article:18955563 | pubmed:author | pubmed-author:HinkeAxelA | lld:pubmed |
| pubmed-article:18955563 | pubmed:author | pubmed-author:LabarBorisB | lld:pubmed |
| pubmed-article:18955563 | pubmed:author | pubmed-author:HajekRomanR | lld:pubmed |
| pubmed-article:18955563 | pubmed:author | pubmed-author:EgyedMiklósM | lld:pubmed |
| pubmed-article:18955563 | pubmed:author | pubmed-author:AdamZdenekZ | lld:pubmed |
| pubmed-article:18955563 | pubmed:author | pubmed-author:KuhnIngridI | lld:pubmed |
| pubmed-article:18955563 | pubmed:author | pubmed-author:TóthováElenaE | lld:pubmed |
| pubmed-article:18955563 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18955563 | pubmed:day | 9 | lld:pubmed |
| pubmed-article:18955563 | pubmed:volume | 113 | lld:pubmed |
| pubmed-article:18955563 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18955563 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18955563 | pubmed:pagination | 3435-42 | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:meshHeading | pubmed-meshheading:18955563... | lld:pubmed |
| pubmed-article:18955563 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:18955563 | pubmed:articleTitle | Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. | lld:pubmed |
| pubmed-article:18955563 | pubmed:affiliation | Department of Medicine I, Wilhelminenspital Vienna, Vienna, Austria. heinz.ludwig@wienkav.at | lld:pubmed |
| pubmed-article:18955563 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18955563 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:18955563 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:18955563 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18955563 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18955563 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18955563 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18955563 | lld:pubmed |
